Topics: Oncology, Dose-Escalation, East ESCALATE, CRM, Early Phase Trials, Eearly Development, BLRM, biostatistics, EAST 6.4, adaptive trials
Traditional rule-based approaches to dose escalation such as 3+3 are widely used in early clinical development. They can be appealing due to the simplicity of execution. However, estimates produced may be highly variable and the targeting of true Maximum Tolerated Dose may be poor. Bayesian dose escalation approaches in early phase trials can offer an effective alternative to determining the maximum tolerable dose of a new drug more quickly, as well as ensuring that all of the information available to trial clinicians is taken into account so that the patients enrolled in the trial receive the best possible treatment.
Topics: Dose-Escalation, East ESCALATE, CRM, BLRM, biostatistics, EAST 6.4, adaptive trials
If you’re in the practice of conducting early phase clinical trials, you’ve probably heard that modern trial designs include a number of new methodologies. There’s CRM and BLRM, model-based methods versus rule-based methods, and a number of other developments that might affect your clinical strategy. Each of these methods affects operational, financial and regulatory objectives in unique ways.
As a part of this year’s Joint Statistical Meeting, Cytel statisticians created a primer to go along with a workshop for early phase clinical trial design.
In the primer you will find:
- 1. An overview of 3+3, CRM, BLRM and mTPI methods
- 2. A synopsis of basic concepts like Bayesian and frequentist statistics, models and rules, etc.
- 3. Reflections on regulatory considerations
- 4. Case studies and topical exercises with Cytel’s high-powered simulations
- 5. A solution guide for those with access to Cytel's East software
Click to download the Primer
Topics: Bayesian Methods, CRM, Early Phase Trials, Clinical Development Strategy, BLRM
Bayesian Trial Designs are Safe, Efficient & Flexible: A Review of Published Phase 1 Studies
Posted by Charles Liu
Aug 21, 2014 10:03:33 AM
Use of the continual reassessment method (CRM) is safe, efficient, and flexible, according to a comprehensive review of 53 published Phase I trials from 2003-2013. The review, just published in the Journal of Clinical Oncology by leading researchers Iasonas and O'Quigley, challenges common misconceptions about model-based dose escalation designs.
Topics: Dose-Escalation, CRM, Phase 1
The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics. Sign up for updates direct to your inbox. You can unsubscribe at any time.
Posts by Topic
- Adaptive Clinical Trials (77)
- biostatistics (77)
- Clinical Research Services (46)
- Statistical Programming (44)
- Clinical Development Strategy (42)
- Clinical Data (33)
- Oncology (32)
- adaptive designs (32)
- adaptive trials (31)
- Data Management (26)
- Bayesian Methods (25)
- Statistical Analysis (22)
- Cytel Consulting (20)
- Interim Analyses (19)
- Early Phase Trials (18)
- Cytel Strategic Consulting (16)
- Phase 3 (16)
- EAST 6.4 (15)
- Phase 1 (15)
- Trial Design (15)
- pharmacometrics (15)
- Cyrus Mehta (14)
- Dose-Escalation (14)
- Regulation (14)
- SAS (14)
- data manager (14)
- patient enrollment (14)
- CDISC (13)
- EDC (13)
- East (13)
- Dose-Finding (12)
- clinical development (12)
- phase 2 (12)
- Cardiovascular (11)
- Promising Zone (11)
- Entrepreneurship (10)
- database build (10)
- Biometrics (9)
- FDA (9)
- SDTM (9)
- Statistical Innovations in Clinical Development (9)
- pharmacology (9)
- Access to Slides PDF (8)
- East 6.3 (8)
- Precision Medicine (8)
- adaptive sample size re-estimation (8)
- sample size re-estimation (8)
- CDM (7)
- Case Study (7)
- Multi-Arm Multi-Stage Studies (7)
- Multi-Arm Studies (7)
- Simulations (7)
- Trial Quality (7)
- clinical trials (7)
- outsourcing (7)
- BLRM (6)
- Bayesian (6)
- CRO (6)
- DMC (6)
- East ESCALATE (6)
- East PREDICT (6)
- Enrichment (6)
- Nitin Patel (6)
- Program and Portfolio Optimization (6)
- R programming (6)
- Software Simulations (6)
- Training and Education (6)
- careers (6)
- data science (6)
- enforesys (6)
- feasibility studies (6)
- ADaM (5)
- Cytel Videos (5)
- MCP-Mod (5)
- Marvin Zelen (5)
- R (5)
- Sample Size (5)
- big data (5)
- clinical data management (5)
- clinical research (5)
- go-no-go (5)
- ACES (4)
- Access to Paper PDF (4)
- Biomarkers (4)
- CDASH (4)
- CRM (4)
- Exact Tests (4)
- Prediction (4)
- Predictive Enrichment (4)
- R language (4)
- Rare Disease (4)
- Recruitment (4)
- Rstats (4)
- Safety (4)
- Small Sample Sparse Data (4)
- StatXact (4)
- Trial Monitoring (4)
- forecasting (4)
- model-informed-drug-development (4)
- Cytel Events (3)
- Dose Selection (3)
- Group Sequential (3)
- JSM (3)
- PK/PD (3)
- Proof-of-Concept (3)
- R&D (3)
- Seamless designs (3)
- Simulation & Biomarkers (3)
- Statistical Puzzles (3)
- Trial Design Software (3)
- White Paper (3)
- custom software (3)
- exact statistics (3)
- optimization (3)
- p value (3)
- type 1 error (3)
- Adaptive Finance (2)
- Blind and Unblind Trials (2)
- Compass (2)
- Computing (2)
- EMA (2)
- Education (2)
- Efficacy (2)
- Lingyun Liu (2)
- Medical Devices (2)
- Monte Carlo (2)
- Movers & Shapers (2)
- NONMEM (2)
- PMDA (2)
- PSI Conference (2)
- Pediatric (2)
- basket trials (2)
- biomedical signals (2)
- personalized medicine (2)
- psychiatry and neuroscience (2)
- real world evidence (2)
- trial planning (2)
- Adaptive Licensing (1)
- Antibiotic resistance (1)
- Biosimilars (1)
- Composite Endpoints (1)
- Cytel CliPLab (1)
- Cytel Congratulates (1)
- East Recruit (1)
- Eearly Development (1)
- Evidence Based Medicine (1)
- Exact Inference (1)
- Exact tests for categorical data (1)
- FMCG (1)
- Fourier (1)
- HTA (1)
- ISE (1)
- ISS (1)
- Infectious Diseases (1)
- NICE (1)
- PIPE (1)
- PhUSE (1)
- Phase I (1)
- Predicted Interval Plots (1)
- RFP (1)
- Richard Branson (1)
- Risk Based Monitoring (1)
- Sam Hsaio (1)
- Scope conference (1)
- Statistics Article full PDF (1)
- Translational Medicine (1)
- Translational Statistics (1)
- Webinar Slides (1)
- What are... (1)
- benefit risk assessment (1)
- estimands (1)
- genetic algorithm (1)
- health economics (1)
- infographic (1)
- machine learning (1)
- medical ethics (1)
- medical writing (1)
- meta-analysis (1)
- non parametric analysis (1)
- pattern recognition (1)
- permutations (1)
- pharmacovigilance (1)
- quantitative decision-making (1)
- randomization (1)
- signal detection (1)
- signal processing (1)
- statistical communication (1)
- subgroup analysis (1)
- t-tests (1)
- time to event trials (1)
- time-to-even trials (1)
- treatment switch (1)